^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    istiratumab (MM-141)

    i
    Other names: MM-141, MM 141
    Associations

    News

    Trials
    Company:
    Ipsen
    Drug class:
    HER3 inhibitor, IGF-1R inhibitor
    Related drugs:
    Associations

    News

    Trials
    over3years
    Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). (PubMed, Ann Oncol)
    Istiratumab failed to improve the efficacy of SOC chemotherapy in this patient setting. High serum IGF-1 levels did not appear to be an adverse prognostic factor when compared with non-biomarker-selected historic controls.
    Clinical • P2 data • Journal
    |
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    gemcitabine • albumin-bound paclitaxel • istiratumab (MM-141)